Showing 7961-7970 of 10259 results for "".
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Sate
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Jan Marini Launches New Peel Systemhttps://practicaldermatology.com/news/20130206-jan_marini_launches_new_peel_system/2459619/Jan Marini Skin Research launched the Marini Peel Systems, which combine peels with concentrated retinol, peptides, and antioxidants for individuals seeking more aggressive treatments for issues ranging from sun damage to skin coloration. The systems include the Refine Peel, for skin rejuvenation, t
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- Obagi and Suneva Partner to Distribute Facial Rejuvenation Complexhttps://practicaldermatology.com/news/20130201-obagi_and_suneva_parter_to_distribute_facial_rejuvenation_complex/2459622/Obagi Medical Products and Suneva Medical jointly announced a partnership to co-distribute ReGenica Facial Rejuvenation Complex, a product that accelerates the appearance of post-laser skin through the fusion of stem cells and growth factors. It contains the Multipotent CCM Complex (Cell Conditioned
- AADA Applauds Proposed Legislation to Repeal Medicare's IPABhttps://practicaldermatology.com/news/20130130-aada_applauds_proposed_legislation_to_repeal_medicares_ipab/2459624/The American Academy of Dermatology Association (AADA) issued a statement applauding the introduction of the Protecting Seniors' Access to Medicare Act, legislation that would repeal the Independent Payment Advisory Board (IPAB) created by the 2010 Affordable Care Act. The AADA argues that the IPAB
- Survey: Women Want Youthful Skin Over Fancy Wardrobehttps://practicaldermatology.com/news/20130124-survey_women_want_youthful_skin_over_fancy_wardrobe/2459628/The Syneron Consumer Beauty Insights Survey of more than 1,000 women over age 25 reports that 79 percent prefer having youthful skin that would make them feel more confident than a designer wardrobe. Findings also show that only eight percent of women are satisfied with their current appearance. In
- Provectus Launches Free Investor Relations Apphttps://practicaldermatology.com/news/20130124-provectus_launches_free_investor_relations_app/2459627/Provectus Pharmaceuticals, Inc. launched a free mobile shareholder investor relations application. The app offers immediate portable access to the company's latest news, financial information, presentations, and factsheet. The "Provectus IR" app is a
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intol